The impact of BRAF mutations on the clinical outcomes of PTC remains debatable. In ATCs,
in turn, BRAF mutations identify patients eligible for targeted therapy, which is now …

Simple Summary Thyroid-stimulating hormone (TSH) plays a role in the regulation of thyroid
hormones and is an important indicator for assessing thyroid function. Thyroid cancer (TC) is …

Recurring evidence suggests that fasting has extensive antitumor effects in various cancers,
including papillary thyroid carcinoma (PTC). However, the underlying mechanism of this …

Thyroid cancer is the most common endocrine malignancy and several genetic events have
been described to promote the development of thyroid carcinogenesis. Besides the effects of …

Simple Summary Increased oxidative stress (OS) has been implicated as a relevant risk
factor for cancer development and progression. The incidence of differentiated thyroid …

Radioiodine (RAI) refractory differentiated thyroid cancer is an uncommon and challenging
situation that requires a multidisciplinary approach to therapeutic strategies. The definition of …

Papillary thyroid carcinomas (PTCs) are driven by a variety of molecular abnormalities
including BRAF, RAS, ALK, RET, and NTRK alterations. PTCs driven by the BRAFV600E …

Increasingly sensitive diagnostic methods, better understanding of molecular
pathophysiology, and well-conducted prospective studies have changed the current …

Background: Papillary thyroid cancer (PTC) is one of the most common endocrine
malignancies with different risk levels. However, preoperative risk assessment of PTC is still …

Thyroid lobectomy has gained increasing popularity over the past decade as a treatment for
differentiated thyroid cancer (DTC), largely due to a rise in the diagnosis of low-risk cancers …